FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1361-1362 March 25, 2004 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Lin, M.-T. PubMed Citation

To the Editor: Lin et al. (Dec. 4 issue)¹ conclude that recipients of allogeneic bone marrow who have the interleukin-10 (IL10) –592A/A genotype have a lower risk of severe acute graft-versus-host disease (GVHD) than recipients who have the –592C/C genotype. The authors hypothesize that a high level of interleukin-10 production is associated with the –592A/A genotype and mitigates the intensity of GVHD-induced inflammation. However, Lin et al. did not measure serum interleukin-10 levels in the recipients they studied. Miura et al. have reported that patients with the IL10 –592A/C genotype or –592A/A genotype have reduced levels of IL10 . . . [Full Text of this Article]

This article has been cited by other articles:

• Lin, M.-T., Storer, B., Martin, P. J., Tseng, L.-H., Grogan, B., Chen, P.-J., Zhao, L. P., Hansen, J. A. (2005). Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor {beta} genotype of donor. Blood 106: 3995-4001 [Abstract] [Full Text]